News

Rxilient is pleased to announce that it has entered a partnership with Polichem, a subsidiary of Almirall S.A., for two dermatology products:

We're pleased to share that 露美瑞乳膏 Lumirix® (Ruxolitinib) Cream 15mg/g has received official approval in Taiwan.

​Rxilient Medical and Delova Biotech have entered into an exclusive licensing for the commercialization of QP001, a novel long-acting meloxicam injection for post-operative pain management. QP001 has already been approved and marketed in the United States under the brand name Qamzova, and in China as 普坦宁® (Putanning).

Rxilient Announces Licensing Agreement with Formosa Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

On 29 December, 2023, Rxilient Health Pte. Ltd. (“Rxilient Health”) is pleased to announce that PharmaGend Global Medical Services Pte. Ltd. (“PharmaGend”), jointly invested by Rxilient Health, and its main shareholder CMS, through its wholly-owner affiliate CMS MEDICAL VENTURE PTE. LTD., with Pharmaron (Hong Kong) International Limited (“Pharmaron”) * and HEALTHY GOAL LIMITED (“Legend Fund”), has entered into a lease agreement for the building and property located in Tuas, Singapore and completed the purchase of certain production machines and equipment from Strides Pharma Global Pte. Ltd. ( defined as “Singapore manufacturing plant ”).

We are pleased to release the news that on 27 March 2023, through Rxilient Biotech Pte. Ltd. (“Rxilient Biotech”) and Excellmab Pte. Ltd. (“Excellmab”) entered into a Shareholders’ Agreement (the “Shareholders’ Agreement”) with Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司, “Junshi Biosciences”), pursuant to which Junshi Biosciences will subscribe for the shares newly issued by Excellmab in a non-monetary manner to obtain 40% equity interest.